MedPath

Phase II study of second line chemotherapy with carboplatin and paclitaxel for metastatic melanoma

Phase 2
Recruiting
Conditions
melanoma
Registration Number
JPRN-UMIN000003260
Lead Sponsor
Division of Skin Oncology, Comprehensive cancer center, Saitama medical university International medical center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have brain metastases which are not controlled by surgery or radiotherapy 2. Patients without myelosuppresion-Neutrophilic leukocyte<1,500/mm3, PLT<100,000/mm3 3. Patients with severe disorders in heart (NYHA Grade 2 or more), lung, liver, kidney or brain. 4. Patients who are pregnant or nursing 5. Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy of combination therapy with carboplatin and paclitaxel in patients with metastatic melanoma
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath